Track market-moving stories before they get noisy

113 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Zscaler CEO, chairman and founder Jay Chaudhry joins 'Making Money' to explain why AI is driving the biggest security shift in decades and what consumers need to know.

On its third quarter of 2026 earnings call, held on Oct. 22, 2026, Ryder (R +2.02%) raised its full-year 2026 comparable earnings per share forecast range to $14.85 to $15.05. The shift toward contractual asset-light operations provides predictable earnings that protect returns during cyclical downturns. Three things management said stand out.

1. Asset-Light Growth Transforms the Revenue BaseSupply Chain Solutions, which handles warehousing and logistics, and Dedicated Transportation Solutions, which supplies customized vehicle fleets, now drive most of the business. This structural expansion reduces reliance on capital-heavy commercial truck leasing.

Our revenue mix has shifted toward Supply Chain and Dedicated, with approximately 60% of 2026 expected revenue generated by these asset-light businesses, compared to 44% in 2018, as a result of organic growth, strategic acquisitions, and innovative technology.
-- John Diez, Chief Executive Officer2. Cash Generation Unlocks Multibillion-Dollar Capital DeploymentLong-term contractual relationships generate steady operating cash flows and de-lever the balance sheet rapidly. This capital capacity gives management room to balance organic fleet investments with share repurchases and strategic acquisitions.

This leaves around $4.5 billion, which equates to approximately 50% of our quarter end market cap, available for flexible deployment to support growth and return capital to shareholders.
-- Cristy Gallo-Aquino, Executive Vice President and Chief Financial Officer3. Commercial Rental Fleet Signals an Inflection PointFleet Management Solutions, which handles vehicle leasing and maintenance, recorded commercial rental fleet utilization of 77%. Improving spot rates and leaner used vehicle inventories are driving higher transactional demand across tractor classes.

We are seeing good activity on the Industrial side, on the Dedicated sales activity. And then Rental, we did see an acceleration in both tractors and trailers, which is indicative of maybe this freight market showing signs of life, which is one of the encouraging signs we saw in the quarter.
-- John Diez, Chief Executive OfficerLooking AheadFreight conditions show early stabilization as commercial fleet utilization trends higher across core operating units. Ryder's long-term contractual model locks in steady pricing and predictable cash generation across market cycles.

And finally, we are encouraged to see benefits across the business from continued strengthening of freight market conditions. Contractual sales remain strong across all three segments, with activity accelerating in Leased and Dedicated.
-- John Diez, Chief Executive OfficerManagement is tracking rental fleet expansion timing and pricing discipline on contractual renewals. Reduced balance sheet leverage positions the company to capture profitable market share as freight demand recovers.

We continue to outperform prior cycles, and our results are benefiting from consistent execution and the strength of our contractual portfolio. We continue to see significant opportunity for profitable growth, supported by secular trends, our operational expertise, and ongoing momentum from multi-year strategic initiatives.
-- John Diez, Chief Executive OfficerThe Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

On Oct. 20, Space Exploration Technologies (SPCX +1.89%) reported its 2026 third-quarter earnings, posting some impressive numbers.

According to CNBC-tracked analyst estimates, revenue of $14.5 billion easily topped the $12.7 billion expected, and adjusted earnings per share of $0.45 once again beat the $0.13 expected. In addition, SpaceX reported net income of $4.4 billion, a vast improvement over the prior-year net loss of more than $1 billion.

After that report, anyone who hasn't invested in SpaceX yet may be wondering whether they should have bought shares earlier and if it's too late to buy the stock. To answer that question, I'll look at SpaceX's trading history and what's ahead for the company.

Image source: Getty Images.

Get comfortable with price swings SpaceX has only traded publicly since June, but anyone who bought shares and held since then has experienced wild price swings. Shares opened to the public on June 12 at $150 and closed on June 16 at $211.39. After that, however, the stock price was trading as low as $104.83 on Aug. 3.

It then rallied to close at $171.92 on Oct. 6, but it dropped again, closing at $147.79 on Oct. 20. After the Oct. 20 earnings report, however, it opened at $160.56 on Oct. 21.

The point in sharing all that price action is that investing in SpaceX requires a lot of conviction, paired with the ability to handle rapid, steep declines. Without either, it can be easy to have a knee-jerk reaction if the price starts dropping and end up selling for a loss.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

It's still early Before SpaceX went public, it was viewed as a space company. That's not how it viewed itself, however, as SpaceX listed in its S-1 filing that its total addressable market (TAM) was an ambitious $28.5 trillion, with $26.5 trillion of that coming from opportunities in artificial intelligence (AI).

Its AI division is showing promise, generating $7.6 billion in revenue, up from $813 million in the prior-year period. On top of that, $7.6 billion in AI revenue means the AI division accounted for more than half of SpaceX's $14.5 billion in total revenue.

That said, there's still a long way to go to capture even more of that projected $26.5 trillion TAM. SpaceX could have a first-mover advantage in establishing a new wave of AI infrastructure through space-based data centers, but scaling will take time. It filed an application to launch 1 million satellites into space to serve as data centers, but the earliest those are expected to launch is 2028.

The final verdict on investing in SpaceX Even though the stock price may be climbing after its earnings, as shown from its price history, it's going to go through ups and downs. Also, the company is still in the early stages of pursuing the AI opportunities it believes it has.

Putting that all together, for any investor who plans to hold shares for the long haul and can handle stock price turbulence, it is absolutely not too late to buy SpaceX stock or to invest in an exchange-traded fund that holds it.

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.Investors who lost money on Moderna, Inc. securit.

Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels

Clinical activity with Sofe-M was maintained even in patients with prior PARP inhibitor exposure, patients who typically experience poor outcomes with platinum-based chemotherapy

Sofe-M is currently being studied in both platinum-sensitive and platinum-resistant ovarian cancer in multiple Phase 3 studies as part of the FRAmework-01 master protocol

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its investigational folate receptor alpha (FRα) antibody-drug conjugate (ADC) sofetabart mipitecan (Sofe-M) plus bevacizumab achieved a confirmed objective response rate (cORR) of 79% and a disease control rate (DCR) of 100% in patients with platinum-sensitive ovarian cancer (PSOC). A cORR of 79% or higher was seen in both poly (ADP-ribose) polymerase inhibitor (PARPi)-treated and PARPi-naïve patients. These data will be shared in an oral presentation at the European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain.

FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells. Sofe-M is an FRα-targeting ADC composed of an Fc-silent, FRα-specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker. The antibody is designed to bind FRα on the surface of tumor cells, delivering exatecan directly into the tumor cell to disrupt DNA replication.

Jacob Van Naarden, Executive Vice President and President of Lilly Oncology: "The standard of care for platinum-sensitive ovarian cancer has remained unchanged for a decade and demands new treatment options. Results for Sofe-M show a promising efficacy and tolerability profile across both platinum-resistant and platinum-sensitive ovarian cancer, regardless of FRα expression levels or prior treatment. These data give us confidence as we continue to study Sofe-M in our Phase 3 FRAmework-01 program to bring this potential new medicine to the women who need it."

The Phase 1 study is evaluating Sofe-M plus bevacizumab in patients with advanced solid tumors, including a cohort of 33 women with PSOC who received Sofe-M (4 mg/kg) plus bevacizumab (15 mg/kg). Patients received a median of three prior systemic regimens (range 1–6), including prior PARPi (67%) and prior bevacizumab (70%). As of the July 6, 2026, data cutoff, the cORR among the 29 patients with measurable disease was 79.3% (23/29; 6 complete responses [CR, 20.7%] and 17 partial responses [PR, 58.6%]), and DCR was 100%. Responses were consistent across FRα expression levels and prior PARPi exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively.

Chrisann Kyi, MD, Gynecologic Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center: "The durable and robust responses we've seen in patients with platinum-sensitive ovarian cancer are important, particularly in a PARPi pretreated population, where the response rate seen with Sofe-M exceeds what has been reported in published platinum re-challenge studies. The observed safety profile and low discontinuation rates, combined with early efficacy results, support the continued investigation of Sofe-M as a potentially meaningful new option for patients."

Sofe-M plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine. No new safety signals were observed. The most common treatment-emergent adverse events (TEAEs) across all patients included epistaxis (73%), nausea (73%), anemia (58%), neutropenia (55%), and fatigue (52%). The most common Grade ≥3 TEAEs were neutropenia (42%) and anemia (24%); febrile neutropenia occurred in 3% of patients, and G-CSF prophylaxis was not mandated. Any-grade neuropathy occurred in 9% of patients, with no Grade ≥3 events. Dose reductions occurred in 42% of patients, and 6% discontinued treatment due to an adverse event.

The FRAmework-01 program is evaluating Sofe-M in three global Phase 3 trials across both platinum-resistant and platinum-sensitive ovarian cancer: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

For more information on Lilly's oncology pipeline, click here.

Frequently Asked Questions

What is sofetabart mipitecan (Sofe-M)? Sofetabart mipitecan (Sofe-M) is an investigational folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) being studied for the treatment of ovarian cancer and other solid tumors. It is designed to selectively bind to cancer cells expressing FRα and deliver a topoisomerase I inhibitor payload directly to those cells. What is an antibody-drug conjugate? An antibody-drug conjugate (ADC) is a type of medicine that pairs an antibody with a cell-killing payload. The antibody is designed to recognize and bind to a specific protein found on the surface of cancer cells, and the payload is released once the ADC reaches its target, allowing the medicine to attack cancer cells while limiting exposure to healthy tissue.1 How is Sofe-M different from other FRα-targeted ADCs? Sofe-M is designed to target FRα across a broad range of expression levels, including in tumors with lower FRα expression. In this Phase 1 study, Sofe-M plus bevacizumab showed a confirmed objective response rate of 79.3% in platinum-sensitive ovarian cancer (PSOC), with consistent activity across FRα expression levels and regardless of prior PARP inhibitor exposure. Earlier studies in platinum-resistant ovarian cancer (PROC) also demonstrated responses observed across all FRα expression levels and in patients previously treated with mirvetuximab soravtansine (MIRV).2 These results are being further evaluated in Lilly's ongoing Phase 3 FRAmework-01 program, which is studying Sofe-M across both platinum-resistant and platinum-sensitive ovarian cancer. What are the results with sofetabart mipitecan (Sofe-M) in the treatment of platinum-sensitive ovarian cancer (PSOC)?The Phase 1 study demonstrated encouraging clinical activity, including a confirmed objective response rate (cORR) of 79.3% and a disease control rate (DCR) of 100%, in heavily pretreated patients with platinum-sensitive ovarian cancer. Activity was observed across FRα expression levels and regardless of prior PARP inhibitor exposure. Median duration of response (DOR) and median progression-free survival (PFS) were not reached at median follow-ups of 6.2 and 10.2 months, respectively. Sofetabart mipitecan (Sofe-M) plus bevacizumab demonstrated a safety profile consistent with the known profiles of each medicine, with no new safety signals observed and a low rate of discontinuation due to adverse events (6%). These findings support continued investigation of Sofe-M in the ongoing Phase 3 FRAmework-01 trial. In this study Sofe-M was dosed at 4 mg/kg. Why is it dosed at 3mg/kg in the Phase 3 FRAmework-01 trial? The 3 mg/kg dose of Sofe-M was selected as the recommended phase 3 dose (RP3D), based on analysis of the safety, efficacy and PK data as monotherapy. The ORR was comparable between the two doses, with ORRs of 59.0% (95% CI 42.1, 74.4) and 58.8% (95% CI 32.9, 81.6), at 4 mg/kg and 3mg/kg doses, respectively. Safety signals were higher at 4 mg/kg versus 3 mg/kg, with Grade ≥3 TRAEs at 56.4% vs 35.3% and dose reductions of 41.0% vs 23.5%. What are historical clinical trial results for standard of care in platinum-sensitive ovarian cancer (PSOC)? For patients who recur after platinum-based chemotherapy and PARP inhibitor (PARPi) maintenance, published real world data on subsequent platinum re-challenge have shown modest response rates, with an objective response rate (ORR) of 41.9%.3 Other studies of platinum-based regimens, such as OCEANS, were conducted prior to the routine use of PARPi maintenance and did not include patients previously treated with a PARPi,4 a population that now represents a majority of patients with recurrent PSOC, including those enrolled in Sofe-M's Phase 1 study. What is platinum-sensitive ovarian cancer (PSOC)? Platinum-sensitive ovarian cancer (PSOC) is characterized as ovarian cancer that comes back more than six months after platinum-based chemotherapy. While people with PSOC can often be treated with platinum again, the disease tends to return, and each recurrence can leave fewer treatment options and shorter remissions.5 What is the current unmet need in platinum-sensitive ovarian cancer (PSOC)? The standard of care for PSOC has remained largely unchanged for more than a decade, even as understanding of which patients benefit from it has evolved. Approximately 50% of PSOC patients have HRD-positive tumors, meaning their tumors carry a specific DNA-repair deficiency.6 These patients tend to have longer progression-free survival with upfront platinum-based chemotherapy plus a PARP inhibitor (PARPi).6 However, when these patients do recur after PARPi maintenance, response rates to subsequent platinum-based treatment are modest.6 Patients with non-HRD-positive tumors see minimal benefit from PARPi to begin with and generally have a poorer prognosis overall.6 Despite these different outcomes between HRD-positive and HRD-negative patients, treatment approaches for PSOC have not meaningfully changed to reflect that distinction. What is the difference between platinum-resistant (PROC) and platinum-sensitive ovarian cancer (PSOC)?The difference comes down to timing. If ovarian cancer returns more than six months after platinum-based chemotherapy, it's considered platinum-sensitive, and patients often respond well to platinum treatment again. If the cancer returns within six months, or continues growing during treatment, it's considered platinum-resistant, and platinum-based chemotherapy is generally no longer effective. Because platinum resistance tends to develop gradually, each recurrence can bring a shorter remission, even while a patient's disease is still classified as platinum-sensitive.6 What is folate receptor alpha (FRα), and why is FRα expression level important in treating ovarian cancer? FRα is expressed in almost all ovarian cancers, at much higher levels than in healthy tissue, making it a target that can help direct treatment to tumor cells.7 FRα expression level refers to the amount of the protein present on a tumor and may influence eligibility for or response to certain FRα-targeted therapies.7 How is the FRAmework-01 clinical trial designed? FRAmework-01 is a global, three-part Phase 3 trial studying sofetabart mipitecan (Sofe-M) across both platinum-resistant and platinum-sensitive ovarian cancer in a single program: Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The trial's main measure of success across all three parts is how long patients go without their cancer progressing. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT). Enrollment is ongoing globally with first registrational dose in Q4 2025 for PROC and in Q1 2026 for PSOC.

About Ovarian Cancer

Ovarian cancer is the sixth leading cause of cancer death among women in the United States.8 While most patients initially respond to platinum-based chemotherapy, approximately 70% will experience recurrence, leading to progressively shorter remission periods with each subsequent treatment.6 When cancer recurs during or within six months of platinum therapy, known as platinum-resistant disease, patients face limited treatment options.6,9

About Sofetabart Mipitecan

Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth. FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers. Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 program. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).  

About FRAmework-01

FRAmework-01 (NCT07213804) is a Phase 3, randomized, open-label, three-part study evaluating sofetabart mipitecan (Sofe-M; LY4170156) in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Part A tests Sofe-M as monotherapy in platinum-resistant disease; Part B tests Sofe-M plus bevacizumab in platinum-sensitive disease that progressed on or within six months of completing a PARPi; and Part C tests Sofe-M plus bevacizumab in PARPi-naïve platinum-sensitive disease. The primary endpoint is progression-free survival (PFS), assessed by the investigator in Part A and by blinded independent central review (BICR) in Parts B and C. Key secondary endpoints are overall survival, objective response rate, duration of response, and safety.  The FRAmework-01 study is in partnership with the European Network for Gynecological Oncological Trial groups (ENGOT - lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

More information on FRAmework-01 can be found on clinicaltrials.gov.

References

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 2. Ray-Coquard, et al. Sofetabart mipitecan, an antibody drug conjugate targeting folate receptor alpha, in high grade ovarian cancer: Results from the first-in-human phase 1 study, Annals of Oncology (2026), doi: https://doi.org/10.1016/j.annonc.2026.10.001. Romeo M, Gil-Martín M, Gaba L, et al. Multicenter real-world data of subsequent chemotherapy after progression to PARP inhibitors in a maintenance relapse setting. Cancers (Basel). 2022;14(18):4414. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045. Lesnock JL, Temin S, Bouberhan S, et al. Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. J Clin Oncol. Published online July 13, 2026. doi:10.1200/JCO-26-01591. Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304. doi:10.3322/caac.21559. Bax HJ, Chauhan J, Stavraka C, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128(2):342-353. doi:10.1038/s41416-022-02031-x. American Cancer Society. Cancer Facts for Women. Accessed September 9, 2026. https://www.cancer.org/cancer/risk-prevention/understanding-cancer-risk/cancer-facts/cancer-facts-for-women.html. Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. doi: 10.1093/annonc/mdz062. About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

© Lilly USA, LLC 2026. ALL RIGHTS RESERVED.

MSK Disclosure: Dr. Kyi has financial interests related to Eli Lilly and Company.             

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan plus bevacizumab and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company

Nucor Corporation is well-positioned to benefit from U.S. steel market tailwinds, driven by tariffs and robust infrastructure/data center demand. NUE's flexible cost structure—electric arc furnaces, semi-variable payroll, and vertical integration—provides resilience and cushions against market downturns. Due to lower operating leverage, NUE offers lower earnings volatility, making it attractive for investors seeking stability in a bullish steel cycle.

-

Investigation follows the October 22, 2026 disclosure regarding FirstCash Holdings, Inc.; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on FirstCash Holdings, Inc. ("FirstCash" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of FirstCash Holdings, Inc. (NASDAQ: FCFS) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding FirstCash Holdings, Inc.

Investors who lost money on FirstCash Holdings, Inc. securities can submit their FirstCash Holdings, Inc. loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the FirstCash Holdings, Inc. investigation

Disclosure date: October 22, 2026Stock price decline: $31.97 per share, or 14.75%Closing price after the decline: $184.78 on October 22, 2026What happened?

On October 22, 2026, the Company reported third quarter financial results earnings, including that the Company’s American First Finance (“AFF”) segment operating income fell approximately 28% year over year to $33 million, “due primarily to the loss of earnings from previously reported merchant partner bankruptcies,” referring primarily to Conn’s and American Freight, which filed for bankruptcy in 2024. The Company further reported gross transaction volume of lease and loan originations during the third quarter decreased 15% compared to the prior-year quarter, due in part to an alleged “increased strategic focus on merchant quality.”

On this news, FirstCash shares fell $31.97 per share, or 14.75%, to close at $184.78 on October 22, 2026, thereby injuring investors.

"The price of FirstCash Holdings, Inc. shares fell 14.75% following the October 22, 2026 disclosure that FirstCash's American First Finance segment operating income fell approximately 28% year over year to $33 million and its third quarter lease and loan origination volume decreased 15%. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of FirstCash Holdings, Inc. investors. Investors who lost money can contact Glancy about the FirstCash Holdings, Inc. investigation, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought FirstCash Holdings, Inc. securities and lost money may have claims and can contact Glancy to learn whether they are affected by the FirstCash Holdings, Inc. investigation.

What is a securities fraud investigation? In the FirstCash Holdings, Inc. investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against FirstCash Holdings, Inc., investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents FirstCash Holdings, Inc. investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the FirstCash Holdings, Inc. investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the FirstCash Holdings, Inc. investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about FirstCash Holdings, Inc. should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

FirstCash Holdings, Inc. investigation page, Glancy Prongay Wolke & Rotter LLPFirstCash Q3 ReportFirstCash Holdings, Inc. SEC filings index, EDGARSEC Whistleblower ProgramGlancy Prongay Wolke & Rotter LLPThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Chemours Company (NYSE: CC) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Chemours securities between February 20, 2026 and August 4, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit.

Chemours Case Details

The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that:
      (1)   Defendants had materially overstated aftermarket demand for their Opteon products;
      (2)   demand for such products was decreasing as a result of Defendants’ overselling Opteon products in the preceding fiscal year;
      (3)   as a result of these undisclosed issues, Defendants’ financial guidance for the 2026 fiscal year was unreliable; and
      (4)   as a result, Defendants’ public statements were materially false and misleading at all relevant times.

What's Next for Chemours Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/chemours-company-cc-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Chemours you have until December 7, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Chemours Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Chemours Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

-

MELBOURNE, Fla.--(BUSINESS WIRE)--The Board of Directors of L3Harris Technologies (NYSE: LHX) has declared a quarterly cash dividend of $1.25 per common share, payable Dec. 18, 2026, to shareholders of record as of the close of business on Dec. 4, 2026.

About L3Harris Technologies

L3Harris is the Trusted Disruptor in defense tech. With customers’ mission-critical needs always in mind, our employees deliver end-to-end technology solutions connecting the space, air, land, sea and cyber domains in the interest of national security. Visit L3Harris.com for more information.

More News From L3Harris Technologies

Back to Newsroom

Cathay General Bancorp is rated BUY, with shares up 25% YTD and trading at an attractive valuation relative to sector-leading ROE. CATY's CET1 ratio of 13.5% and low non-performing assets underscore strong credit quality and capital strength. 42% of CATY's loan book will reprice over the next 12 months, supporting NIM and earnings in a higher-rate environment.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A common stock of Duolingo, Inc. (NASDAQ: DUOL) between May 2, 2025 to February 26, 2026, inclusive (the “Class Period”), of the important December 7, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Duolingo Class A common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Duolingo class action, go to https://rosenlegal.com/cases/duolingo-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Daily Active User (“DAU”) growth rates were being leveraged against deliberately added user friction in the form of significant increases in ad volume, subscription tier upsells, and worsened product quality, and defendants understood that any amount of user friction would cause users to leave the app and, ultimately, negatively impact DAU growth rates; (2) Duolingo’s rigorous A/B testing demonstrated to defendants that increased friction in the free user experience was having negative impacts on DAU growth rates; (3) Duolingo’s quickly generated AI content was worsening the quality of Duolingo’s product offerings, negatively impacting the user experience and user trends, and threatening the sustainability of Duolingo’s financial performance; and (4) far from driving sustained growth and strong user momentum through content and “product improvements” that “get improved retention,” Duolingo’s constant A/B testing informed Duolingo that its monetization push and lower-quality, rapidly generated AI content were degrading the Duolingo product experience and the value proposition of its subscription tiers. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Duolingo class action, go to https://rosenlegal.com/cases/duolingo-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

-

Investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation; investors who lost money may have claims to recover their losses

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Integra LifeSciences Holdings Corporation ("Integra" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Integra LifeSciences Holdings Corporation (NASDAQ: IART) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 2, 2026 disclosure regarding Integra LifeSciences Holdings Corporation.

Investors who lost money on Integra LifeSciences Holdings Corporation securities can submit their Integra LifeSciences Holdings Corporation loss information to learn about potentially pursuing claims to recover their losses.

Key facts in the Integra LifeSciences Holdings Corporation investigation

Disclosure date: October 2, 2026Stock price decline: $3.41 per share, or 21.2%Closing price after the decline: $12.68 on October 2, 2026What happened?

On October 2, 2026, Integra announced updated full year guidance and preliminary third quarter results. The Company disclosed, among other things, that due to a July flood at its Cincinnati manufacturing facility, “disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million.” Integra also slashed its 2026 revenue guidance by approximately $30.5 million at the midpoint. 

On this news, Integra shares fell $3.41 or 21.2%, closing at $12.68 on October 2, 2026, thereby injuring investors.

Then, on October 21, 2026, Integra reported final third quarter results. Among other items, the Company disclosed “the Cincinnati disruption proved more significant than initially expected.” The Company announced it expected fourth quarter revenue of $413 million to $433 million (down 0.5% to 5.2%). The Company further disclosed “more measured expectations for portions of our Tissue Reconstruction business” in part because “growth in Tissue Reconstruction did not materialize as anticipated.”

On this news, Integra’s stock fell $1.49 or 11.18% to close at $11.84 on October 21, 2026, thereby injuring investors further.

"The price of Integra LifeSciences Holdings Corporation shares fell 21.2% following the October 2, 2026 disclosure that Integra had cut its 2026 revenue guidance by approximately $30.5 million at the midpoint and said a July flood at its Cincinnati manufacturing facility reduced third quarter revenue by about $7 million and would reduce fourth quarter revenue by $15 million to $20 million. Investors who suffered losses deserve to know whether they were given complete and accurate information prior to the disclosure, and our investigation seeks to answer that question," said Charles H. Linehan, Partner at Glancy Prongay Wolke & Rotter LLP.

What's the next step?

Glancy is investigating potential claims on behalf of Integra LifeSciences Holdings Corporation investors. Investors who lost money can contact Glancy about the Integra LifeSciences Holdings Corporation investigation, email [email protected], or call 310-201-9150 (toll-free: 888-773-9224).

Frequently Asked Questions

Who is eligible? Investors who bought Integra LifeSciences Holdings Corporation securities and lost money may have claims, and can contact Glancy to learn whether they are affected by the Integra LifeSciences Holdings Corporation investigation.

What is a securities fraud investigation? In the Integra LifeSciences Holdings Corporation investigation, Glancy is reviewing whether the Company or its executives may have made false or misleading statements to investors in violation of the federal securities laws.

Has a lawsuit been filed? This release announces Glancy's investigation, not a lawsuit. If a securities class action is later filed against Integra LifeSciences Holdings Corporation, investors may have the opportunity to seek appointment as lead plaintiff.

Does it cost anything to contact Glancy or participate in this investigation? Glancy represents Integra LifeSciences Holdings Corporation investors on a contingency fee basis, so investors pay no attorneys' fees out of pocket. Any attorneys' fees and litigation expenses are paid only from a recovery, if one is obtained, and are subject to court approval.

Why work with Glancy on the Integra LifeSciences Holdings Corporation investigation? Glancy Prongay Wolke & Rotter LLP is a premier law firm with decades of experience representing investors and consumers in securities litigation and other complex class action litigation. Contact Glancy about the Integra LifeSciences Holdings Corporation investigation. Prior results do not guarantee a similar outcome.

Whistleblower notice

Persons with non-public information about Integra LifeSciences Holdings Corporation should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information that leads to a successful SEC enforcement action may receive awards of 10 to 30 percent of the sanctions collected, when those sanctions exceed $1 million. For more information, contact Charles H. Linehan at 310-201-9150 or 888-773-9224, or email [email protected].

About Glancy Prongay Wolke & Rotter LLP

Glancy was named one of Law360's Securities Groups of the Year and ranked second in total investor recoveries by ISS Securities Class Action Services in 2025.

Glancy's successes have been widely covered by leading news and industry publications, including The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.

Prior results do not guarantee a similar outcome.

Related links

Integra LifeSciences Holdings Corporation investigation page, Glancy Prongay Wolke & Rotter LLPIntegra Q3 Financial ResultsIntegra LifeSciences Holdings Corporation SEC filings index, EDGARSEC Whistleblower ProgramGlancy Prongay Wolke & Rotter LLPThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

More News From Glancy Prongay Wolke & Rotter LLP

Back to Newsroom

On October 23, 2026, C3.ai Inc AI shares rose 3.6% to $12.46. This increase is part of a broader trend where the stock has gained 10.1% over the past week and 14.7% over the past month. However, year-to-date, the stock is down 7.6%, and it has decreased 30.6% over the past year, fluctuating between a 52-week high of $18.64 and a low of $7.68.

GF Value™ verdict: Current price of $12.46 vs GF Value of $13.41, indicating a 7.1% undervaluation. GF Score™ is 61/100, which suggests an above-average rating. Most notable signal: Insider activity shows net selling of $75.4M over the past 12 months. Is AI Overvalued or Undervalued? C3.ai Inc currently trades at $12.46, which is below the GF Value™ estimate of $13.41. This suggests that the stock is undervalued by approximately 7.1%. The GF Valuation label indicates that the stock is fairly valued, although this assessment should be taken cautiously given the company's unprofitable status. The GF Value™ is an intrinsic value estimate derived from historical trading multiples, business growth, and future performance projections, providing a directional guide rather than a precise fair value for loss-making companies.

The margin of safety at this price raises some opportunities for investors, however, potential buyers should be aware of the inherent risks associated with investing in a cash-flow-negative entity. The lack of profitability can lead to volatile stock performance, and the company’s financial health needs to be carefully monitored.

How Does AI's Valuation Compare to Its History? Due to the unavailability of Price-to-Earnings (P/E) data for C3.ai, we cannot perform a direct comparison of its current valuation against its historical P/E metrics. Instead, we focus on the Price-to-Sales (P/S) ratio, which is more relevant for unprofitable companies. The historical median P/S ratio for C3.ai is approximately 9.2x. Current valuation metrics do not indicate an alignment with historical averages, but specific P/S data is required for a deeper analysis.

What Does AI's GF Score™ Tell Us? The GF Score™ is a comprehensive measure that evaluates a stock's investment potential based on various factors, including financial strength, profitability, growth, valuation, and momentum. C3.ai's GF Score™ is 61/100, indicating a performance that is above average relative to its peers.

Metric Rating GF Score™ 61 Financial Strength 8/10 Profitability 1/10 Growth 2/10 Valuation 9/10 Momentum 7/10 C3.ai shows strong financial strength with a rating of 8/10, suggesting robust financial health. However, its profitability rank is significantly low at 1/10, indicating challenges in generating profits. The valuation rank of 9/10 supports the notion that the stock may be undervalued, while a momentum rank of 7/10 reflects recent positive price action.

What Are Gurus and Insiders Doing with AI? C3.ai is currently held by four gurus, with two increasing their positions and two reducing their stakes in recent quarters. This mixed activity signals a cautious sentiment among institutional investors. Moreover, insider activity reveals that over the past year, insiders purchased $0.3M worth of shares but sold a substantial $75.7M, resulting in a net selling of $75.4M. Such a pattern of insider selling may raise concerns about the company's future prospects and should be taken into account by potential investors.

What This Means for Investors Based on the GF Value™ analysis, C3.ai Inc appears to be undervalued at its current price of $12.46. However, investors should proceed with caution due to the company's lack of profitability and the notable insider selling activity. This valuation assessment suggests that while there is potential for upside, the risks inherent to the stock must be thoroughly evaluated.

For more detailed information, visit the C3.ai Inc AI stock page to explore further insights and metrics.

Frequently Asked Questions What is AI's GF Score™?

The GF Score™ for C3.ai is 61/100, indicating that it has an above-average investment potential compared to its peers based on various fundamental factors.

Is AI overvalued or undervalued?

According to the GF Value™ analysis, C3.ai is currently undervalued with a price of $12.46 compared to a GF Value of $13.41, representing a margin of 7.1%.

What is AI's P/E ratio?

Currently, C3.ai does not have an available P/E ratio due to its unprofitable status, making a P/E comparison with historical data impractical.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

On October 23, 2026, Capri Holdings Ltd CPRI shares fell 3.0% to a current price of $15.87. The stock has experienced a volatile year, with a 52-week range of $12.40 to $28.27.

GF Value™ verdict: CPRI is currently priced at $15.87, which is 23.6% below the GF Value™ estimate of $20.76.GF Score™ of 67/100 indicates an above-average performance relative to its peers.Most notable signal: Insider activity shows a net selling of $1.3M, with insiders buying $1.0M and selling $2.3M over the past 12 months.Is CPRI Overvalued or Undervalued?According to the GF Value™, Capri Holdings Ltd is currently undervalued, with a significant margin of safety as it trades 23.6% below its intrinsic value estimate of $20.76. This valuation suggests that there is potential for appreciation in the stock price, offering an investment opportunity for those considering entry points. The GF Valuation label of "Modestly Undervalued" reinforces this perspective, indicating that the current market price does not fully reflect the company's inherent value based on historical trading multiples, past business performance, and future growth expectations.

However, while the undervaluation presents an opportunity, potential investors should remain cautious, given the company's financial strength rating of 3/10. This rating indicates that there may be underlying issues that could affect the stock's performance in the future. Therefore, while the current valuation is appealing, it is essential to consider the broader financial context when evaluating the stock.

How Does CPRI's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)17.3x14.9xForward P/E7.5xN/ACurrently, Capri Holdings Ltd has a P/E (TTM) of 17.3x, which is 16% above its 5-year median P/E of 14.9x. The forward P/E of 7.5x indicates a more favorable outlook compared to the trailing metric. This analysis aligns with the GF Value™ verdict, suggesting that while the stock's current P/E is elevated, the potential for future earnings growth is reflected in the lower forward P/E. Overall, CPRI appears to be trading above its historical valuation on a trailing basis, yet the forward outlook remains promising.

What Does CPRI's GF Score™ Tell Us?The GF Score™ is a comprehensive measure that evaluates a stock’s overall performance based on various factors, including financial strength, profitability, growth potential, valuation, and momentum. Capri Holdings Ltd's GF Score™ of 67/100 indicates a competitive standing among its peers, with specific strengths and weaknesses worth noting.

MetricRatingGF Score™67Financial Strength3/10Profitability7/10Growth2/10Valuation10/10Momentum5/10In summary, Capri Holdings Ltd demonstrates a solid valuation rank, scoring a perfect 10/10 in this category, indicating that it is attractively priced relative to its earnings potential. However, weaknesses in financial strength (3/10) and growth (2/10) suggest potential headwinds that could impact future performance. The profitability rank of 7/10 indicates a reasonable level of earnings generation, but the overall score reflects a mixed performance that investors should consider when assessing the stock's profile.

What Are Gurus and Insiders Doing with CPRI?Currently, 11 gurus hold positions in Capri Holdings Ltd, with 4 gurus adding to their stakes while 5 have trimmed their positions in recent quarters. This activity reflects a cautious sentiment among professional investors, suggesting that while some see value in the stock, others may have reservations.

In terms of insider activity, the past 12 months have seen insiders purchase $1.0M worth of shares while selling $2.3M, resulting in a net selling of $1.3M. This net selling could raise some concerns about the insiders' confidence in the company's near-term prospects. While insider buying is generally viewed as a positive signal, the current pattern of selling could indicate that insiders are not as bullish on the stock's future performance, which is an important consideration for potential investors.

What This Means for InvestorsBased on the GF Value™ analysis, Capri Holdings Ltd is currently undervalued, presenting an opportunity for investors. However, the stock's mixed performance across financial strength and growth ranks suggests that caution is warranted. The recent insider selling further complicates the outlook, implying potential risks that investors should carefully weigh against the compelling valuation. For more detailed insights, you can visit the Capri Holdings Ltd CPRI stock page for further analysis and updates.

Frequently Asked QuestionsWhat is CPRI's GF Score™?

CPRI has a GF Score™ of 67/100, indicating that it performs above average compared to its peers.

Is CPRI overvalued or undervalued?

According to the GF Value™, CPRI is currently undervalued, trading 23.6% below its intrinsic value estimate of $20.76.

What is CPRI's P/E ratio?

CPRI has a P/E (TTM) of 17.3x, which is 16% higher than its 5-year median P/E of 14.9x, indicating that it is trading above its historical valuation on a trailing basis.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Space Exploration Technologies (SPCX +1.89%) reported its third-quarter earnings after the market closed on Tuesday, Oct. 20.

Ahead of the report, I laid out what I'd be looking for. And, frankly, the latest report was better than I expected in several key ways. Here's a look at what the company's Q3 earnings showed.

SpaceX's third-quarter results beat expectations
The headline numbers beat Wall Street's targets on the top and bottom lines. SpaceX reported sales of $14.58 billion, well above the $12.72 billion consensus estimate. Diluted earnings were $0.35 per share, beating the $0.13 per share consensus estimate from analysts.

Image source: Getty Images.

Going into the report, I wanted to see whether stronger sales were translating into better profit. It did.

Starlink grows while revenue per user improves
For Starlink, I was especially interested in how much each customer was paying. That figure moved in the right direction.

Average revenue per user, or ARPU, a key figure, rose to $69 a month from $66 last quarter. That's a modest bump, but the trend is what is important. At least for now, it doesn't appear that the company's move into developed markets is affecting the global average.

Still, I wouldn't declare the pricing question settled. It's still pretty early innings, and as time goes on, I still think a higher mix of growth coming from developing nations will lower ARPU and the segment's margins.

Overall, though, the results were strong for the segment, with sales up 69% and operating profit nearly doubling year over year.

Starship's next test is full recovery
For the space business, growth didn't look great. But that was expected as the company has turned its focus on delivering as many Starlink satellites into orbit as it can. The launch business doesn't book any revenue from those. Of course, this dynamic is a big reason why the connectivity segment looks as good as it does.

I was especially interested in what management had to say about Starship, the company's next-generation rocket, designed to be reusable and carry much larger payloads into orbit than the Falcon 9, SpaceX's current workhorse.

SPCX Space Exploration Technologies$147.49+$2.74 (+1.89%)

NASDAQ · As of 4:00 PM ET 10/23/26

The question was whether Starship is getting closer to becoming a reliable, reusable part of the company. What, if any, material updates did the top brass have for the rocket's development timeline?

On the earnings call, Musk said SpaceX expects its next Starship flight in November, when it will attempt to catch both the booster and upper stage as they return to Earth. Management also plans to refly the upper stage and attempt in-orbit refueling early next year.

Those would be meaningful steps toward making Starship a reliable, reusable rocket, and the update gives investors concrete milestones to watch.

AI revenue surges, but spending will accelerate
Right now, the AI business -- or what SpaceX now calls "Super Intelligence" -- is the segment to watch. Revenue reached $7.6 billion, up from $2.6 billion last quarter. Operating profit hit $431 million.

Cursor, the AI coding company SpaceX acquired in August, contributed just $608 million in sales, so most of the growth was organic. It was also a drag on operating profit, which would have come in at about $1.6 billion for the quarter if not for stock compensation expenses related to Cursor.

AI capital expenditures, or capex, while still extremely high, increased modestly, from $15.8 billion to $16.4 billion. However, the company expects that to increase in the fourth quarter. CFO Bret Johnsen told investors to expect total company capex of $35 billion to $40 billion next quarter, with the lion's share going to AI.

A lot went right for SpaceX this quarter. Starlink grew without another decline in ARPU, AI sales are really taking off, and some meaningful progress was made for Starship. Still, capex is accelerating, and the company's financials look considerably worse on a cash basis. Whether that spending will ultimately yield sufficient returns to reward shareholders remains the question that matters most.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Baidu, Inc. (NASDAQ: BIDU) between November 18, 2025 and August 17, 2026, inclusive (the “Class Period”), of the important November 13, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Baidu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Baidu class action, go to https://rosenlegal.com/cases/baidu-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Baidu had overstated the ability of its AI business to mitigate rapid declines in its legacy online marketing business; (2) as a result, Baidu’s revenue was reasonably likely to decline; and (3) as a result of the foregoing, defendants’ positive statements about Baidu’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Baidu class action, go to https://rosenlegal.com/cases/baidu-inc-2026/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Nvidia and TSMC are critical parts of the AI ecosystem, which is why investors have flocked to them in recent years. Nvidia's data center segment now accounts for over 92% of its total revenue.

A Look at PENN Entertainment Inc (PENN) After 6.2% Decline -- GF Value $23.10 vs Price $14.50

Valuation Assessment of PENN Entertainment Inc PENNOn October 23, 2026, PENN Entertainment Inc (PENN) shares fell 6.2%, currently trading at $14.50. This decline is notable within the context of a 52-week range that saw a high of $22.36 and a low of $11.65.

GF Value™ verdict: Current price $14.50 vs GF Value $23.10, indicating a 37.2% undervaluation.GF Score™: 71/100, suggesting an above-average overall performance.Most notable signal: Insider activity with $0.8M net buying over the past 12 months.Is PENN Overvalued or Undervalued?PENN Entertainment Inc is currently trading below its estimated fair value according to the GF Value™, which is set at $23.10. This suggests that the stock is undervalued by approximately 37.2%. However, it is essential to consider that the GF Value™ serves as a directional indicator rather than a precise fair-value target, particularly for a company that is currently unprofitable and cash-flow negative. As a result, while the potential for upside exists, it is accompanied by significant risks, warranting cautious evaluation.

The current financial position of PENN indicates a possible value trap. Investors should be aware that relying solely on earnings-based valuation metrics, such as the P/E ratio, may not provide a reliable assessment due to the company's ongoing losses. Instead, a Price-to-Sales (P/S) analysis is more appropriate, given PENN's historical median P/S ratio of approximately 0.6x. This highlights the importance of examining revenue rather than earnings when evaluating PENN's valuation.

How Does PENN's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)9.5x19.6xPENN's current forward P/E of 9.5x is significantly below its 5-year median P/E of 19.6x, indicating that the stock is trading at a discount compared to its historical valuation. This analysis aligns with the GF Value™ verdict, suggesting that PENN may indeed be undervalued based on its earnings potential.

What Does PENN's GF Score™ Tell Us?The GF Score™ is a comprehensive measure that evaluates a company's performance across several dimensions, including financial strength, profitability, growth potential, valuation, and momentum. PENN's GF Score™ of 71/100 indicates that it is performing above average overall, although there are notable strengths and weaknesses within its sub-ranks.

MetricRatingGF Score™71/100Financial Strength3/10Profitability6/10Growth6/10Valuation4/10Momentum7/10PENN's strongest area lies in its profitability and growth ranks, both scoring 6/10. However, the financial strength rank of 3/10 indicates a weak balance sheet, which presents risks for investors. The valuation rank of 4/10 highlights potential concerns about its current price levels relative to its intrinsic value, reinforcing the caution around its valuation assessment.

What Are Gurus and Insiders Doing with PENN?Currently, 8 gurus are holding shares of PENN, with 3 increasing their positions and 5 reducing their holdings in recent quarters. This mixed activity among gurus suggests a cautious stance on the stock. Notably, insider activity over the past 12 months includes $0.9M in purchases and only $0.1M in sales, resulting in a net buying of $0.8M. This pattern of insider buying may indicate confidence in the company's long-term prospects despite its current operational challenges.

What This Means for InvestorsBased on the analysis of PENN's valuation metrics and the signals from the GF Value™, the stock appears to be undervalued at its current price of $14.50. However, the financial instability and cash-flow negative status raise important considerations for potential investors. Therefore, while there may be opportunities for growth, the inherent risks should not be overlooked.

For more detailed insights and analysis, visit the PENN Entertainment Inc PENN stock page and explore the GF Value™ page for additional context.

Frequently Asked QuestionsWhat is PENN's GF Score™?

PENN's GF Score™ is 71/100, indicating an above-average overall performance relative to its peers.

Is PENN overvalued or undervalued?

PENN is currently undervalued according to the GF Value™, which estimates its fair value at $23.10 compared to the current price of $14.50.

What is PENN's P/E ratio?

PENN's forward P/E is 9.5x, significantly lower than its 5-year median P/E of 19.6x, suggesting the stock is trading at a discount compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

4.4K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NNN, O, ADC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AppLovin Corporation (NASDAQ: APP) between February 12, 2026 and August 5, 2026, inclusive (the "Class Period"), of the important November 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased AppLovin securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Vertex’s Crinetics Deal Balances Growth with Integration RiskVertex Pharmaceuticals NASDAQ: VRTX outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD.

Chief Executive Officer and President Reshma Kewalramani said the company has four renal diseases in mid- or late-stage development: AMKD, IgA nephropathy, membranous nephropathy and autosomal dominant polycystic kidney disease, or ADPKD. She said Vertex views the combined opportunity across those diseases as potentially comparable to a $10 billion franchise, though she characterized that as her view of the market opportunity.

Get Vertex Pharmaceuticals alerts:

CRISPR Therapeutics Gains After Earnings as Pipeline Hope GrowsKewalramani said povetacicept, acquired through Vertex’s Alpine acquisition, is being developed for B-cell-driven diseases including IgA nephropathy, membranous nephropathy and myasthenia gravis. She added that the FDA action date for povetacicept in IgA nephropathy is Nov. 30.

Povetacicept Phase III Interim Results
Richard Lafayette, professor of medicine at Stanford University, reviewed interim results from RAINIER, a global Phase III randomized, double-blind, placebo-controlled study of povetacicept in adults with biopsy-proven IgA nephropathy.

How Royalty Pharma Prints Cash Without Biotech's Biggest RisksPatients entered the study with urine protein-to-creatinine ratios above 0.75 grams per gram and estimated glomerular filtration rates above 30 mL/min. They were receiving maximally tolerated renin-angiotensin system inhibition, with stable use of other standard therapies, including SGLT2 inhibitors, mineralocorticoid receptor antagonists and, where available, endothelin blockers.

Participants were randomized two-to-one to receive povetacicept or placebo every four weeks. Lafayette said the interim analysis at 36 weeks showed a 52% reduction in proteinuria with povetacicept. He described the reduction as rapid, sustained and consistent across evaluated subgroups, including those defined by age, race, baseline proteinuria, kidney function, hematuria and SGLT2 inhibitor use.

The presentation also cited an approximately 80% reduction in galactose-deficient IgA1, a disease-related biomarker, at the end of the interim analysis period. More than 80% of treated patients with baseline hematuria had resolution by 20 weeks, according to Lafayette. Nearly half of patients reached a urine protein-to-creatinine ratio below 0.5 grams per gram, while nearly one in six achieved normal proteinuria by week 36.

Lafayette said the safety profile observed to date was similar to placebo, aside from generally mild injection-site reactions. There were no deaths reported during the interim period. He said povetacicept is administered as a once-monthly subcutaneous injection and is expected to be available in an auto-injector format in the open-label extension.

While Lafayette called the results “transformational efficacy,” he cautioned that comparisons with other BAFF/APRIL-targeting therapies remain premature. He said longer-term estimated glomerular filtration rate, or eGFR, results will be important for comparing kidney-function protection across treatments.

Inaxaplin and APOL1-Mediated Kidney Disease
Akinlolu Ojo, executive dean of the School of Medicine at the University of Kansas, discussed results from the AMPLIFIED study of inaxaplin in patients with AMKD who were not included in the Phase III AMPLITUDE trial.

AMPLIFIED included two cohorts: patients with low levels of proteinuria and patients with moderate proteinuria who also had diabetic kidney disease. Ojo said participants were already receiving contemporary background therapy for chronic kidney disease and, where applicable, diabetic nephropathy.

He said inaxaplin produced substantial and clinically meaningful reductions in urinary protein excretion in both cohorts. In the cohort with diabetic kidney disease, proteinuria reductions ranged from 17% to 25%. Ojo noted that confidence intervals crossed one in that cohort but argued the magnitude of reduction could still have longer-term clinical significance, citing historical results from the RENAAL trial of losartan in diabetic nephropathy.

Ojo said the larger Phase III AMPLITUDE study is fully enrolled, with 522 total participants, including 66 patients carried forward from a Phase IIb study and 456 newly enrolled Phase III participants. Vertex expects to share interim-analysis results early next year.

He said AMKD patients typically experience eGFR declines of roughly 5 to 8 mL/min per year, making a one-year kidney-function endpoint meaningful in this population. Kewalramani clarified that Vertex’s agreement with the FDA for potential accelerated approval of inaxaplin is based on one-year eGFR results, rather than proteinuria alone.

Commercial and Access Plans
Chief Commercial Officer Duncan McKechnie said Vertex has been engaging with commercial payers and pharmacy benefit managers regarding povetacicept since July 2025. He said about 70% of IgA nephropathy patients are commercially insured and that the company expects to provide more specific coverage updates during the first half of 2027.

McKechnie said Vertex expects some patients to receive treatment on a case-by-case basis before formal coverage arrangements are established and plans to offer a bridge program. He also said the company is not expecting payers to require step therapy through other APRIL/BAFF products.

Kewalramani said Vertex plans to discuss the future development path for inaxaplin in diabetic kidney disease with the FDA after AMPLITUDE results are available.

About Vertex Pharmaceuticals (NASDAQ:VRTX)Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?Before you consider Vertex Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.

While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds persons or entities that: (a) sold shares of Dun & Bradstreet Holdings, Inc. (NYSE: DNB) (“D&B”) common stock in the open market from May 13, 2025 through August 26, 2025; (b) exchanged shares of D&B common stock into the August 26, 2025 merger of D&B with affiliates of Clearlake Capital Group, L.P. for $9.15 per share in cash (the “Merger”); and/or (c) held shares of D&B common stock as of the May 9, 2025 Record Date for the special meeting of stockholders and whose shares were voted on, or entitled to vote on, the Merger, of the important November 10, 2026 lead plaintiff deadline.

SO WHAT: If you sold Dun & Bradstreet common stock, held shares of D&B common stock on May 9, 2025, or exchanged shares of D&B common stock as a result of its merger, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Dun & Bradstreet class action, go to https://rosenlegal.com/cases/dun-bradstreet-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The lawsuit seeks to recover damages on behalf of investors that were damaged as a result of allegedly false and misleading statements and omissions of material facts in D&B’s March 23, 2025 announcement of the Merger and the May 13, 2025 definitive proxy statement on Schedule 14A (the “Proxy”). Among other things, the complaint alleges the Proxy and other solicitation materials misled investors regarding the true value of D&B and the subject transaction, including portraying the Merger as the product of an ordinary-course strategic review and organic arm’s-length interest in D&B, while omitting Executive Chairman Foley’s personal interest in a quick sale. The complaint also alleges the Proxy omitted Bank of America Securities’ valuations of superior alternatives to a whole-company sale, misstated that D&B’s Board of Directors had approved downward revisions to D&B’s financial projections and failed to disclose long-standing, material ties between Foley and D&B’s financial and legal advisors.

To join the Dun & Bradstreet class action, go to https://rosenlegal.com/cases/dun-bradstreet-holdings-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

Nine popular cryptocurrencies trade under $1 right now, but steep price drops and ballooning token supplies mean most of them face serious headwinds. A few stand out from the pack, and the reasons why may surprise even seasoned crypto investors.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

For investors looking for the best crypto under $1, nine well-known options to consider range from TRON (CRYPTO:TRX) to Pepe. Unfortunately, many of these have seen significant price drops over the past month.  Bitcoin (CRYPTO:BTC) is trading at $81,449, down 6.9% in 2026, and smaller coins have fared even worse.

Low prices often attract buyers who believe cheaper coins have more growth potential. However, price alone doesn’t determine value. Market capitalization, calculated by multiplying the price by the number of coins in circulation, reflects how much investors think the entire network is worth. Any price rally needs to lift this overall market value.

So, out of these nine cryptocurrencies, which one is best positioned for growth in the remainder of 2026? We assessed them based on revenue, momentum, losses from their all-time highs, growth drivers, and overall risk.

Nine Popular Coins Trade Under $1, but Their Values Differ Widely

In addition to TRON and Pepe (CRYPTO:PEPE), this group includes Dogecoin (CRYPTO:DOGE), Cardano (CRYPTO:ADA), Stellar (CRYPTO:XLM), Sui (CRYPTO:SUI), Hedera (CRYPTO:HBAR), Shiba Inu (CRYPTO:SHIB), and Ondo (CRYPTO:ONDO).

Coin
Price
Market Value
30-Day Move
Below Record

TRON
$0.33
$31.4 billion
-3.7%
23.5%

Dogecoin
$0.08
$12.6 billion
-19.3%
89.0%

Cardano
$0.22
$8.2 billion
-13.7%
93.0%

Stellar
$0.18
$6.2 billion
-17.5%
79.8%

Sui
$0.997
$4.1 billion
-1.9%
81.4%

Hedera
$0.08
$3.5 billion
-16.3%
85.9%

Shiba Inu
$0.00000511
$3.0 billion
-14.6%
94.1%

Pepe
$0.00000507
$2.1 billion
+7.0%
81.9%

Ondo
$0.43
$2.1 billion
-0.5%
79.7%

Coins with increasing supplies also face challenges. For example, Sui has 4.12 billion tokens in circulation, giving it a market value of about $4.1 billion on a total supply of 10 billion tokens. This means its fully diluted market cap—what it would be valued at if all tokens were available—would be around $9.9 billion.

Ondo has a similar setup, with 4.87 billion tokens circulating, creating a $2.1 billion market cap from the same total supply. As new tokens become available, investors will need to invest more money to keep the price the same. Dogecoin, for instance, has no capped supply and already has 156.43 billion coins in circulation.

TRON Outperforms Rivals in Revenue

TRON generated $23.4 million in fee revenue over one month, according to DefiLlama data up to October 20. This surpasses the combined earnings of Ethereum (CRYPTO:ETH) and Solana (CRYPTO:SOL), and TRON is also the only coin on the list that has gained value over the past year, up 2.4%.

However, Tether (CRYPTO:USDT) accounts for 97.8% of the nearly $95 billion in stablecoins on TRON, so most of its revenue comes from one issuer’s transfers.

Hedera and Stellar show some activity, but their fee earnings are minimal. Hedera’s transactions surged 168.4% in one month, yet HBAR’s price kept declining because transaction fees are only a fraction of a cent. Stellar’s biggest potential comes from the Depository Trust & Clearing Corporation (DTCC) ‘s plans to tokenize assets on Stellar, but this initiative isn’t expected to go live until early 2027, after the 2026 window closes.

Sui, Pepe, and Ondo carry the momentum. Sui’s value rose 37.4% over the last 90 days, while Pepe jumped 61.5% over the same period. Ondo has risen by 20.3% in 2026, making it the top performer among the group. However, as a meme coin, Pepe lacks revenue to support this price increase.

Price Drops Signal Both Opportunities and Risks

Shiba Inu trades 94.1% below its all-time high, Cardano 93%, and Dogecoin 89%. Cardano peaked at $3.09 in September 2021, suggesting it could rebound significantly.

However, these steep declines also suggest that many investors have shifted their focus elsewhere. Cardano has dropped 67% over the last year, while Dogecoin has lost 59.5% of its value. In contrast, TRON is only 23.5% below its peak, suggesting stronger and more consistent demand.

Which Is the Best Crypto Under $1 for 2026?
In our assessment, TRON, Sui, and Ondo have the strongest growth potential. TRON benefits from reliable fee revenue and may surpass its previous high of $0.43 recorded on December 3, 2024, a 30.6% increase, though Tether could move to a cheaper chain. Sui shows the most promising momentum, but much of its token supply has yet to reach the market. Ondo has posted the highest 2026 gain but faces similar dilution concerns.

For any of these coins to grow, Bitcoin would likely need to top $87,498, its 2025 closing price and about 7.4% higher, as its market share eases. Sui would need $1.40, its 2026 opening price, about 40.4% higher. If Bitcoin drops instead, Sui, Ondo, and Pepe could quickly lose their gains. TRON has the best chance of a new record by December 31, while Sui has the most upside in a Bitcoin recovery.

Contact [email protected] for any questions or corrections.

New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fluence Energy, Inc. (NASDAQ: FLNC) between November 24, 2025 and September 16, 2026, inclusive (the "Class Period"), of the important November 30, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Fluence Energy securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Fluence Energy class action, go to https://rosenlegal.com/cases/fluence-energy-inc-2026-09/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 30, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and misleading statements and/or failed to disclose that: (1) Fluence Energy's ability to deliver its backlog and recognize the revenue underlying its fiscal 2026 guidance depended on new contract manufacturing facilities, including facilities that were not completed, not operational, and/or not capable of producing at the volumes the guidance assumed; (2) the corrective measures Fluence Energy had implemented to address production problems at its contract manufacturers were not remediating those problems, which persisted and extended to Fluence Energy's new facilities; (3) as a result, a material portion of the backlog that defendants represented as "securing" or "covering" Fluence Energy's fiscal 2026 revenue guidance were likely to be delivered and recognized in fiscal 2026; and (4) as a result of the foregoing, defendants' positive statements about Fluence Energy's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Fluence Energy class action, go to https://rosenlegal.com/cases/fluence-energy-inc-2026-09/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/320790

Source: The Rosen Law Firm PA

Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us